NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: gefitinib
Other: laboratory biomarker analysis

First Posted Date: 2003-11-06

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 59

Registration Number: NCT00071994

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

A Phase II Study of UCN-01 in Metastatic Melanoma

Phase 2

Terminated

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: 7-hydroxystaurosporine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-11-06

Last Posted Date: 2015-03-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00072189

Locations: 🇺🇸
UC Davis Cancer Center, Sacramento, California, United States

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Stage IIIA Endometrial Carcinoma
Endometrial Adenosquamous Cell Carcinoma
Endometrial Papillary Serous Carcinoma
Endometrial Adenocarcinoma
Stage IIIB Endometrial Carcinoma
Stage IIIC Endometrial Carcinoma
Endometrial Clear Cell Carcinoma
Recurrent Endometrial Carcinoma
Stage IVA Endometrial Carcinoma
Stage IVB Endometrial Carcinoma

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2003-11-06

Last Posted Date: 2015-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00072176

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Carcinoma
Primary Peritoneal Carcinoma
Stage IV Ovarian Cancer

Interventions: Biological: Bevacizumab
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-11-05

Last Posted Date: 2015-05-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00072566

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps

Phase 3

Completed

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: celecoxib
Other: placebo

First Posted Date: 2003-11-05

Last Posted Date: 2013-04-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1170

Registration Number: NCT00005094

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Phase 1

Completed

Conditions: Disseminated Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma

Interventions: Biological: monoclonal antibody Ch14.18
Drug: isotretinoin
Biological: aldesleukin
Biological: sargramostim

First Posted Date: 2003-11-05

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT00005576

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Phase 1

Completed

Conditions: Advanced Adult Primary Liver Cancer
Anaplastic Thyroid Cancer
Bone Metastases
Carcinoma of the Appendix
Distal Urethral Cancer
Fallopian Tube Cancer
Gastrinoma
Glucagonoma
Inflammatory Breast Cancer
Insulinoma

Interventions: Biological: recombinant interleukin-12
Biological: ABI-007/carboplatin/trastuzumab

First Posted Date: 2003-10-29

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00004074

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Urinary Vitamin C Loss in Diabetic Subjects

Recruiting

Conditions: Diabetes

First Posted Date: 2003-10-28

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 5000

Registration Number: NCT00071526

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Interventions: Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: valspodar

First Posted Date: 2003-10-28

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 640

Registration Number: NCT00003190

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2003-10-28

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT00003595

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
San Francisco General Hospital Medical Center, San Francisco, California, United States

and more 10 locations

Home Terms & Conditions Privacy Policy